Payment overview · 2025
General Payments
$5,568.29
61 reported records · 18 companies
Healthcare provider profile · identity verified
Lan Mo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · NEW YORK, NY · NPI 1760786388
Verified facts
What the public records show
CMS Open Payments records show Lan Mo, M.D. received $5,568.29 in general payments during 2025 across 61 reported records.
AstraZeneca Pharmaceuticals LP accounted for 79.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lenvima, Tagrisso.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Tagrisso by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GILOTRIF as an associated drug or biological on 78 records involving 65 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gilotrif by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lenvima as an associated drug or biological on 16833 records involving 7014 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lenvima by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Imbruvica by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lenvima by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $4,428.72 | 79.5% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $156.91 | 2.8% | 10 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $149.29 | 2.7% | 9 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $125.33 | 2.2% | 5 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.2% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $100.99 | 1.8% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $86.72 | 1.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $76.57 | 1.4% | 4 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $52.22 | 0.9% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.66 | 0.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.48 | 0.8% | 2 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.28 | 0.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.00 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.35 | 0.4% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $21.05 | 0.4% | 1 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $21.03 | 0.4% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.25 | 0.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.44 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $4,100.00 | 2 |
| Food and Beverage | $1,368.30 | 58 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $2,522.23 | 4 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $1,765.00 | 2 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $102.26 | 7 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $86.72 | 4 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $75.35 | 6 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $73.94 | 3 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $72.90 | 3 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.12 | 3 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $53.79 | 2 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $53.79 | 2 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $52.22 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $51.66 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $47.20 | 2 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $31.14 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $31.14 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $31.00 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Lenvima lenvima |
2025 | Lenvima | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 183 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
183 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | GILOTRIF open payments reported associated product |
CMS Open Payments — General Payments 78 supporting records · 65 recipient NPIs · example record 1222734360 |
Gilotrif · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Lenvima open payments reported associated product |
CMS Open Payments — General Payments 16833 supporting records · 7014 recipient NPIs · example record 1244455619 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tagrisso | Osimertinib Mesylate | 183 | 35 |
| Ondansetron Odt | Ondansetron | 73 | 35 |
| Eliquis | Apixaban | 61 | 14 |
| Prednisone | Prednisone | 60 | 25 |
| Abiraterone Acetate | Abiraterone Acetate | 52 | 14 |
| Hydrocortisone | Hydrocortisone | 39 | 18 |
| Omeprazole | Omeprazole | 27 | 12 |
| Hydroxyurea | Hydroxyurea | 26 | suppressed |
| Anastrozole | Anastrozole | 24 | suppressed |
| Xtandi | Enzalutamide | 24 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 23 | 11 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Gilotrif | Afatinib Dimaleate | 17 | suppressed |
| Lenvima | Lenvatinib Mesylate | 16 | suppressed |
| Alecensa | Alectinib Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | 11 |
| Imbruvica | Ibrutinib | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Doptelet | Avatrombopag Maleate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,568.29 · 61 records | AstraZeneca Pharmaceuticals LP | AKEEGA, BALVERSA, CABOMETYX, DARZALEX, DATROWAY, ERLEADA, Enhertu, FRUZAQLA, Fabhalta, IMFINZI, KEYTRUDA, LYNPARZA, Lenvima, MONJUVI, NINLARO, Nubeqa, OPDIVO, PADCEV, PYRUKYND, QINLOCK, REVUFORJ, ROMVIMZA, Stivarga, TAGRISSO, TALVEY, TECVAYLI, Tibsovo, Tivdak, Vanflyta, Vitrakvi, Xofigo, ZYNYZ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lenvima play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error